A two-stage, single-blind, dose-escalating study to assess efficacy and safety of resiquimod gel applied 5 times per week for up to 12 weeks for the treatment of common warts in adults.
Phase of Trial: Phase II
Latest Information Update: 16 Feb 2007
At a glance
- Drugs Resiquimod (Primary)
- Indications Warts
- Focus Therapeutic Use
- 16 Feb 2007 Companies (Medicis Pharmaceutical Corporation, Graceway Pharmaceuticals) identified as trial sponsor and aditional lead centre reported by ClinicalTrials.gov.
- 10 Nov 2006 Status change
- 18 Nov 2005 New trial record.